A broadened study of this group revealed that TIMP-1 promotes melanoma cell survival by activating the PDK1 signaling pathway, and enhances resistance to anoikis through simultaneous activity with PKC, especially in advanced tumor stages 12. Here, PDK1 is linked to neoplasm.